Gen-Probe, Inc. (NASDAQ:GPRO)
| CAPS Rating |
|
|---|---|
| Open | $68.57 |
| Previous Close | $68.90 |
| Daily Range | $68.40 - $69.64 |
| 52-Week Range | $53.92 - $86.96 |
| Market Cap | $3.34B |
| P/E Ratio | 28.60 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 319,546 |
| Average Daily Volume | 0 |
How do you think GPRO will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GPRO Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GPRO News and Commentary
- Here's Why Gen-Probe's Latest Report Might Worry You – The Motley Fool
- 1 Reason Gen-Probe's Earnings Aren't So Hot – The Motley Fool
- Gen-Probe Passes This Key Test – The Motley Fool
- Gen-Probe Earnings Preview – The Motley Fool
- 1 Reason Becton, Dickinson May Be Headed for a Slowdown – The Motley Fool
- A Hidden Reason Why the Future Looks Bright for Gen-Probe – The Motley Fool
- Intuitive Surgical's Management Is Creating Value – The Motley Fool
- Gen-Probe's CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Can You Amass a Fortune With These Stocks? – The Motley Fool
- Becton, Dickinson Passes This Key Test – The Motley Fool
- Is Gen-Probe Going to Burn You? – The Motley Fool
- Are the Earnings at Qiagen Hiding Something? – The Motley Fool
- Qiagen Aims To Buy French Blood Cancer Diagnostics Group Ipsogen – SmartMoney
- Gen-Probe Shares Plunged: What You Need to Know – The Motley Fool
- UPDATE: Thermo Fisher To Buy Allergy Tester Phadia For EUR2.47 Billion – SmartMoney
- Thermo Fisher To Buy Allergy Testing Co Phadia For EUR2.47 Billion – SmartMoney
- Cinven Sells Phadia To Thermo Fisher For EUR2.47 Billion – SmartMoney
- Cramer's Mad Money - A Kinder, Gentler Pipeline Play (4/28/11) – SeekingAlpha
- 6 Major Mid Cap Gainers From Thursday and How to Trade Them Now – SeekingAlpha
- Gen-Probe Shares Popped: What You Need to Know – The Motley Fool

RSS Headlines
Fool UK